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Abstract
Introduction The purpose of this retrospective study was to
determine the clinical utility of serum HER2/neu in monitoring
metastatic breast cancer patients undergoing trastuzumab-
based therapy and to compare these results with those obtained
using cancer antigen (CA) 15-3. We also sought to determine
whether early changes in serum HER2/neu concentrations
could be a predictor of progression-free survival.
Methods Sera were obtained retrospectively from 103 women
at four medical institutions. Patients eligible for participation
were women with metastatic breast cancer who had HER2/neu
tissue overexpression and were scheduled to be treated with
trastuzumab with or without additional therapies as per the
established practices of the treating physicians. A baseline
serum sample for each patient was taken before trastuzumab-
based therapy was started. Patients were subsequently
monitored over 12 to 20 months and serum samples were taken
at the time of clinical assessment and tested with Bayer's
HER2/neu and CA15-3 assays.
Results Concordance between clinical status in patients
undergoing trastuzumab-based treatment and HER2/neu and
CA15-3 used as single tests was 0.793 and 0.627,
respectively, and increased to 0.829 when the tests were used
in combination. Progression-free survival times did not differ
significantly in patients with elevated baseline HER2/neu
concentrations (≥  15 ng/mL) and those with normal
concentrations (<15 ng/mL). However, progression-free
survival differed significantly (P = 0.043) according to whether
the patient's HER2/neu concentration at 2 to 4 weeks after the
start of therapy was >77% or ≤  77% of her baseline
concentration. The median progression-free survival times for
these two groups were 217 and 587 days, respectively. A
similar trend was observed for a subcohort of patients treated
specifically with a combination of trastuzumab and taxane.
Conclusion These findings indicate that serum HER2/neu
testing is clinically valuable in monitoring metastatic breast
cancer patients undergoing trastuzumab-based treatment and
provides additional value over the commonly used CA15-3 test.
The percentage of baseline HER2/neu concentrations in the
early weeks after the start of therapy may be an early predictor
of progression-free-survival.
Introduction
The human-epidermal-growth-factor receptor 2 (HER2, also
known as neu, ErbB-2, and p185HER2) is a transmembrane
glycoprotein with an intracellular tyrosine kinase activity and an
extracellular domain very similar to those of the epidermal-
growth-factor-binding domain of the epidermal-growth-factor
receptor [1]. The HER2/neu proto-oncogene is amplified and/
or overexpressed in approximately 20 to 25% of invasive
CA = cancer antigen; ELISA = enzyme-linked immunosorbent assay; ECD = extracellular domain; FISH = fluorescence in situ hybridization; FDA = 
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breast cancers [2,3]. HER2/neu overexpression has been
associated with a poor rate of disease-free survival [4]. The
role of HER2/neu as a predictive marker of response to hor-
mone therapy and chemotherapy is controversial [5-8]. The
extracellular domain (ECD) of the HER2/neu protein is fre-
quently cleaved and released into the circulation, where it can
be detected by ELISA in up to 45% of patients with metastatic
breast cancer [9]. Rising serum HER2/neu concentrations
have been associated with progressive metastatic disease
and poor response to chemotherapy and hormonal therapy
[10]. Lipton and colleagues [11] showed that patients with an
elevated HER2/neu ECD before therapy were less likely to
respond to second-line endocrine therapy. The same team
evaluated the predictive role of serum HER2/neu ECD in a ran-
domized clinical trial of tamoxifen versus letrozole for patients
with metastatic breast cancer. In that trial, patients with low
concentrations of circulating HER2/neu ECD had improved
response rates and time to progression of disease if they had
been treated with letrozole. In patients with an elevated HER2/
neu ECD, however, there were no significant differences in
outcome between patients treated with tamoxifen and those
treated with letrozole [12].
Trastuzumab (Herceptin™, Genentech, South San Francisco,
CA, USA) is the only HER2/neu-directed therapy approved by
the Food and Drug Administration (FDA) for the treatment of
patients with metastatic breast cancer. Trastuzumab is a
humanized monoclonal antibody directed against the HER2/
neu ECD. Single-agent response rates range from 12 to 30%,
depending on the HER2/neu status of the tumor and the
patient's prior treatment [13,14]. Response rates and time to
disease progression in patients with metastatic breast cancer
are better when trastuzumab is combined with chemotherapy
than when treatment is with chemotherapy alone [15]. Trastu-
zumab has been shown to be synergistic with a variety of com-
monly used chemotherapies such as paclitaxel, docetaxel,
platinum salts, and vinorelbine [15-17].
The most commonly used methods of selecting patients for
trastuzumab monoclonal antibody therapy are immunohisto-
chemistry and fluorescence in situ hybridization (FISH) [18].
Retrospective studies have shown that HER2/neu gene ampli-
fication, measured using FISH, is the best predictive marker of
response to trastuzumab-based therapy [14]. The role of cir-
culating HER2/neu ECD as a predictive marker of response to
such therapy and its role for monitoring therapy in metastatic
breast cancer are not well defined. For the current retrospec-
tive, multicenter evaluation, we sought to determine the clinical
utility of serum HER2/neu in monitoring metastatic breast can-
cer patients undergoing trastuzumab-based therapies and to
compare these results with those obtained using CA (cancer
antigen) 15-3. Additionally, we sought to determine whether
early changes in serum HER2/neu concentrations can be a
predictor of progression-free survival.
Materials and methods
Patient population
Sera were obtained from 103 subjects meeting the study entry
criteria at four medical institutions: the University of Texas MD
Anderson Cancer Center, Memorial Sloan Kettering Cancer
Center, the Charité Hospital, and the University of California.
The study was reviewed and approved at each site by the local
institutional review board and written informed consent was
obtained from each enrolled subject. Patients eligible for par-
ticipation were women with metastatic breast cancer who had
HER2/neu overexpression as determined by immunohisto-
chemistry (scores of 2+ or 3+ on the Dako Herceptest, Dako
Corp, Carpinteria, CA, USA, or CB11 antibody Pathway, Ven-
tana Medical Systems Inc, Tucson, AZ, USA) or by FISH
(PathVysion HER2/neu method, Vysis Inc, Downers Grove, IL,
USA) or the INFORM HER2/neu gene detection system, Ven-
tana Medical Systems) and who were scheduled to be treated
with trastuzumab with or without additional therapies as per
the established practices of the treating physicians. Patients
were trastuzumab-naive at entry to the study. The first (base-
line) serum sample for each patient was taken before trastuzu-
mab-based therapy was started. Patients were subsequently
monitored over 12 to 20 months during trastuzumab-based
therapy, with at least four subsequent serial serum samples
being collected at least 4 weeks apart, at the discretion of the
physician at the time of clinical assessment.
Evaluation of tumor response
Clinical status was determined by available clinical data in the
form of physical examination and imaging techniques (ultra-
sound, x-ray, computed tomography, magnetic resonance
imaging) at each patient visit. All patients had documented,
measurable metastatic breast cancer at entry to the study.
Response to treatment was assessed according to the criteria
of the World Health Organization [19] or RECIST (response
evaluation criteria in solid tumors) [20]. Clinical status –
whether response was complete or partial and whether dis-
ease was stable or progressive – was determined at each
patient visit. Complete or partial responses were confirmed at
a minimum of 4 weeks after complete or partial response was
observed.
Sample collection and serum HER2/neu antigen testing
Serum samples were processed immediately upon collection
of blood and kept at -20°C or colder. Serum samples were
either tested at the site or were subsequently shipped on dry
ice to Bayer Diagnostics (Tarrytown, NY, USA) for batch test-
ing. Frozen samples were tested immediately upon initial
thawing.
The HER2/neu antigen testing was performed using either the
Bayer Immuno1 or ADVIA Centaur™ automated assays. Both
methods are currently cleared by the FDA with an indication
for follow-up and monitoring of patients with metastatic breast
cancer. Previous studies have shown similar diagnosticAvailable online http://breast-cancer-research.com/content/7/4/R436
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performance of the automated methods, with very high corre-
lation between the methods (r2 = 0.99) (product method
sheet), because the antibodies used for capture and detection
of the circulating HER2/neu antigen are identical for these
methods. A serum HER2/neu concentration of 15 ng/ml has
been defined as the upper limit of normal [21].
The Immuno1 assay technology has been previously
described [21]. Briefly, the ADVIA Centaur HER2/neu assay is
a two-site sandwich immunoassay using direct, chemilumines-
cent technology. The Lite Reagent is composed of the mono-
clonal mouse antibody TA-1 labelled with acridinium ester. The
Fluorescein Conjugate Reagent is composed of the mono-
clonal mouse antibody NB-3 labelled with fluorescein. These
two monoclonal antibodies are specific for unique epitopes on
the extracellular domain of HER2/neu. The Solid Phase is
composed of purified monoclonal mouse capture antibody
(antifluorescein) covalently coupled to paramagnetic particles,
which binds the immunocomplex. The reaction is initiated and
the measured chemiluminescence is directly proportional to
the quantity of HER2/neu antigen in the sample.
Samples were also tested for CA15-3 concentrations using
the ADVIA Centaur automated assay in accordance with the
manufacturer's instructions. Single determinations of HER2/
neu and CA15-3 were obtained on each specimen tested.
Statistical analysis
Monitoring of metastatic breast cancer patients with serum 
HER2/neu
To determine the association between HER2/neu and disease
status throughout the monitoring period, patients with stable
partial or complete response were grouped together and con-
sidered as having no disease progression. This group was
compared with the patients whose disease was progressing.
For each pair of serial measurements, changes in HER2/neu
of ≥  15% or < 15% and in CA15-3 of ≥  21% or <21% were
considered to indicate progression or lack of progression,
respectively. These values (i.e., the 15% or 21% change) were
based on the variability of each marker when tested longitudi-
nally over time in a population of apparently healthy woman
(product method sheets). Concordance with clinical status
was determined for both markers with 95% confidence inter-
vals (CI) as single tests and, when the two markers were used
in combination, as a series test. For a series test, change was
considered positive if it was ≥  15% for HER2/neu and ≥  21%
for CA15-3. All other changes were considered no change.
Concordance estimates and their CIs were obtained using
Windows Excel with the Resampling Stat add-in.
Association between baseline HER2/neu concentrations 
and progression-free survival
To determine whether the baseline concentration of serum
HER2/neu is a predictor of progression-free survival in
patients with metastatic breast cancer treated with trastuzu-
mab-based therapies, time to progression was measured from
baseline to the date of first documented disease progression
Table 1
Characteristics of 103 women with HER2/neu-overexpressing metastatic breast cancer
Patient characteristic n%
HER2/neu overexpressiona
Score 2+ 31 30.1
Score 3+ 72 69.9
Treatment
Single-agent trastuzumab 13 12.6
Trastuzumab + taxane 52 50.5
Trastuzumab + vinorelbine 11 10.7
Trastuzumab + taxane + megestrol acetate 6 5.8
Trastuzumab + taxane + tamoxifen 5 4.8
Trastuzumab + bevacizumab 5 4.8
Trastuzumab + taxane + carboplatin 4 3.9
Trastuzumab + taxane + CMF 3 2.9
Trastuzumab + erlotinib 2 1.9
Trastuzumab + doxorubicin + cyclophosphamide 2 1.9
aScores indicating HER2/neu overexpression as determined immunohistochemically using the Dako Herceptest. CMF, cyclophosphamide, 
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for the serum-positive patient group (pretreatment HER2/neu
≥  15 ng/ml) as compared with the serum-negative patient
group (pretreatment HER2/neu <15 ng/ml), using the Kap-
lan–Meier method. A log-rank test was used to determine if
significant difference in progression-free-survival existed
between the two groups.
Association between percentage of baseline HER2/neu 
concentrations after 2 to 4 weeks of therapy and 
progression-free survival
Where possible based on serum sample availability, the per-
centage of baseline HER2/neu concentrations at 2 to 4 weeks
of therapy was determined for a patient. ROC (receiver oper-
ating characteristic) curve analysis as a function of the per-
centage of change in the HER2/neu concentrations between
baseline and 2 to 4 weeks after initiation of therapy was used
to determine the optimal cutoff point. Progression-free survival
was compared between the groups of patients above and
below the cutoff point using the Kaplan–Meier method. A log-
rank test was used to determine significant difference in pro-
gression-free-survival between the two groups.
Kaplan–Meier analysis and graphs were generated using
SPSS (Statistical Package for the Social Sciences) for Win-
dows (version 11.0).
Results
This retrospective study included a total of 103 women with
HER2/neu-overexpressing metastatic breast cancer treated
with trastuzumab-based therapies. The mean serum HER2/
neu concentration at baseline was 170.3 ng/mL, with a
median of 24.0 ng/mL. The mean HER2/neu value for patients
with an immunohistochemistry score of ≤  2+ was 182.8 ng/
mL. For patients with an immunohistochemistry score of 3+,
the mean Her-2/neu value was 201.8 ng/mL; a two-sample t-
test indicated that the difference was not significant (t  =
0.118, df = 74, P = 0.9). The mean serum CA15-3 concentra-
tion at baseline was 224.4 ng/mL, with a median of 42.6 ng/
mL. The average age of the patients at entry to the study was
54 years (range 26 to 97 years). Table 1 shows the character-
istics of the patients with respect to grade of HER2/neu over-
expression and treatments.
To assess the clinical value of serum HER2/neu in monitoring
patients longitudinally over the time course of trastuzumab-
based treatment, a total of 99 of the evaluable patients with
both HER2/neu and CA15-3 measurements were evaluated.
These patients generated a total of 362 visit pairs for analysis.
The median of time points was 4. Table 2 shows the estimates
of concordance with clinical status for each method alone and
in combination as a series test. HER2/neu showed considera-
bly greater concordance than CA15-3 in patients monitored
longitudinally, and when the two tests were used in
combination, the concordance with clinical status was slightly
better than when HER2/neu was used alone.
Baseline concentrations of serum HER2/neu were elevated
(that is, ≥  15 ng/mL) in 70% (72) of the 99 evaluable patients.
Of the 27 patients with a normal HER2/neu baseline value,
disease progressed in 21, and Her-2/neu values were availa-
ble for 20 of these at the time when progression was found: 7
(35%) had elevated HER2/neu values at that time. Of the 27
patients with normal baseline values of Her-2/neu, 10 who
were receiving the trastuzumab–taxane combination had pro-
gression of their disease and 3 of these 10 had elevated
HER2/neu values at the time of the progression.
Kaplan–Meier analysis in patients with elevated baseline con-
centrations of HER2/neu (≥  15 ng/mL) versus those with nor-
mal baseline concentrations (<15 ng/mL) showed no
significant differences in progression-free survival between
these two groups (log-rank statistic = 2.38, df = 1, P > 0.05).
The median follow-up was 237 days. The median progression-
free survival times were 324 days for patients with normal
baseline values of HER2/neu and 462 days for those with ele-
vated baseline values.
We determined the association between percentage of base-
line HER2/neu concentrations at 2 to 4 weeks after the start
of therapy and progression-free survival in a subcohort of 26
evaluable patients. Nineteen of these patients were treated
with trastuzumab (Herceptin) in combination with a taxane;
one received Herceptin in combination with vinorelbine; and
six received single-agent Herceptin, without chemotherapy.
Figure 1 represents the ROC (receiver operating characteris-
tic) curve for disease progression as a function of the percent-
age of change in HER2/neu from baseline to 2 to 4 weeks
after initiation of therapy. The area under the curve is 0.72
(95% CI 0.52 to 0.92). This value of the area under the curve
indicates that the variable (percentage of change in HER2/neu
from baseline) discriminates between those patients whose
Table 2
Estimates of concordance of serum values with clinical status of patients treated with trastuzumab
Concordance HER2/neu CA15-3 Series testa
Cb 0.793 0.627 0.829
aChange was considered positive if it was ≥  15% for HER2/neu and ≥  21% for CA15-3. bDifferences in concordance for HER2/neu and CA15-3 
with 95%CI = 0.166 (lower limit 0.102, upper limit 0.227).Available online http://breast-cancer-research.com/content/7/4/R436
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disease progressed and those whose disease did not
progress.
Examination of the coordinates of the curve indicates that an
optimal cutoff point for the variable is 77%. At this value, the
true-positive fraction is 72.7%, with a true-negative fraction of
53.3%. In addition, the odds ratio for progression is 1.56,
which is a relative maximum at the cutoff.
Figure 2 shows the Kaplan–Meier curves for progression-free
survival in patients with >77% of baseline concentrations of
HER2/neu and ≤  77% of baseline HER2/neu concentrations.
The difference between the median progression-free survival
times for these two groups, 217 and 587 days, respectively,
was significant (log-rank statistic 4.04, df = 1, P = 0.043).
A subcohort of 52 patients treated specifically with a combi-
nation of trastuzumab and taxane was stratified according to
the patients' baseline HER2/neu concentrations; 35 had ele-
vated baseline concentrations (≥  15 ng/mL) and 17 had base-
line concentrations <15 ng/mL. Kaplan–Meier analysis for
progression-free survival in these two groups showed no
significant differences (log-rank statistic = 0.00, df = 1, P =
0.12).
Additionally, we evaluated, in a subpopulation of 15 patients,
the association between percentage of baseline HER2/neu
concentrations found 2 to 4 weeks after the start of trastuzu-
mab–taxane therapy and progression-free survival. The
median progression-free survival in the group of patients
whose HER2/neu value fell to ≤  77% of baseline (median
decrease for the cohort) at 2 to 4 weeks of therapy was 587
days, whereas in the group whose HER2/neu values were
>77% of baseline values, the median progression-free survival
time was 119 days (Fig. 3). Although there was no significant
difference observed in progression-free survival for these two
groups of patients (log-rank statistic = 3.40, df  = 1, P  =
0.065), there was a trend that was similar to that observed for
the larger cohort of patients who were undergoing any of the
trastuzumab–based therapies included in our study.
Discussion
In this cohort, the HER2/neu ECD concentration after 2 to 4
weeks of treatment relative to that at baseline predicted pro-
gression-free survival in patients undergoing trastuzumab-
based therapy for metastatic breast cancer. Since most
patients would not usually undergo imaging studies for
assessment of their response to therapy after 2 to 3 months,
the serum HER2/neu ECD data may be clinically useful to
determine if an individual patient is responding, or whether ear-
lier imaging studies are warranted. Furthermore, in our
patients, the serum HER2/neu ECD provided additional value
over tumor marker CA15-3.
Currently, patients with metastatic breast cancer are selected
for trastuzumab-based therapy if the HER2/neu protein is
overexpressed (immunohistochemistry score 3+) in the pri-
mary tumor, or if FISH provides evidence of HER2/neu gene
amplification [14,15,22]. Although the HER2/neu ECD assay
is approved by the FDA for monitoring patients undergoing
systemic therapy for metastatic breast cancer, the clinical util-
ity of this marker in patients undergoing trastuzumab-based
therapy is not well defined. In 2000, the American Society of
Clinical Oncology Tumor Markers Expert Panel did not recom-
mend the use of CEA, CA15-3, CA27-29, or HER2/neu ECD
to monitor patients with metastatic breast cancer [23].
Although a rising tumor marker may be detected sooner than
radiologically visible progression or than symptoms, available
data do not indicate that this approach would lead to improved
survival in patients with metastatic breast cancer. However, as
novel targeted therapies are developed, specific assays such
as the HER2/neu ECD may gain clinical utility [24].
At the time of the report of the expert panel of the American
Society of Clinical Oncology, there were no published data
regarding circulating HER2/neu ECD and response to trastu-
zumab-based therapy. Since then, several preliminary studies
Figure 1
ROC curve analysis for progression of metastatic breast cancer in 26  patients ROC curve analysis for progression of metastatic breast cancer in 26 
patients. Nineteen of these patients were treated with trastuzumab 
(Herceptin) in combination with a taxane, one with trastuzumab (Her-
ceptin) in combination with vinorelbine, and six with single-agent Her-
ceptin without chemotherapy. The curve shows disease progression as 
a function of the percentage of change in the HER2/neu concentration 
from baseline to 2 to 4 weeks after the start of therapy. HER, human-
epidermal-growth-factor receptor; ROC, receiver operating 
characteristic.
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have found that serum HER2/neu followed the course of dis-
ease while patients were receiving trastuzumab monoclonal
antibody therapy. Esteva and colleagues [25] evaluated serum
HER2/neu in 30 women with tissue HER2/neu overexpressing
metastatic breast cancer who were undergoing weekly
docetaxel and trastuzumab therapy. They found that serum
HER2/neu concentrations decreased in 87% of the respond-
ing patients, indicating that changes in serum HER2/neu con-
centrations correlate well with the clinical course of disease.
Furthermore, they showed that patients with elevated pretreat-
ment serum concentrations (≥  15 ng/mL) of HER2/neu had a
high (76%) overall response rate to therapy, compared with a
33% response rate in patients with baseline concentrations
<15 ng/mL. Dnistrian and collaborators [26] evaluated serum
HER2/neu in 54 patients who had metastatic breast cancer
with tissue overexpression of HER2/neu and who were under-
going trastuzumab therapy either alone or in combination with
paclitaxel. Similar to the results of Esteva and colleagues, they
Figure 2
Kaplan–Meier curves for progression-free survival in patients with metastatic breast cancer given trastuzumab-based treatment Kaplan–Meier curves for progression-free survival in patients with metastatic breast cancer given trastuzumab-based treatment. Curves were plotted 
for two groups of patients, those whose HER2/neu concentrations seen at 2 to 4 weeks of trastuzumab-based therapy were ≤  77% of the baseline 
concentrations and those for whom it was >77% (median progression-free survival time 587 and 217 days, respectively) df = 1. HER, human-epi-
dermal-growth-factor receptor.
Figure 3
Kaplan–Meier curves for progression-free survival in patients with metastatic breast cancer receiving trastuzumab–taxane Kaplan–Meier curves for progression-free survival in patients with metastatic breast cancer receiving trastuzumab–taxane. Differences between the 
survival times (days) for patients whose HER2/neu concentrations at 2 to 2 weeks of treatment had fallen to ≤  77% of baseline values and those 
whose values had remained at >77% of baseline values (respective survival times 587 and 119 days).
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found that among patients with an abnormal pretreatment
serum HER2/neu, 83% responded favorably to trastuzumab
therapy. Futhermore, Kostler and coworkers [27] evaluated
the clinical utility of serum HER2/neu in the early prediction of
response to trastuzumab-based therapy in 55 patients with tis-
sue HER2/neu-overexpressing metastatic breast cancer. They
found that the ratio of the relative values of HER2/neu from
each serial sample during trastuzumab treatment to the base-
line HER2/neu concentration before initiation of trastuzumab
therapy were significantly decreased in patients responsive to
treatment in the early weeks after initiation of therapy. These
authors showed that serial HER2/neu concentrations could
predict the risk for disease progression as early as day 15 of
treatment.
Burstein and collaborators [28] measured HER2/neu ECD
concentrations at baseline and during treatment with vinorel-
bine and trastuzumab. In that study, HER2/neu ECD concen-
trations were not predictive of response to therapy, but a lack
of decline in that concentration was a predictor for tumor pro-
gression after cycle 1. In our retrospective study, baseline
HER2/neu ECD concentrations were not predictive of
response to therapy or time to progression. However, patients
who had ≤  77% of baseline in serum HER2/neu ECD concen-
trations 2 to 4 weeks after initiation of therapy had a longer
time to progression (median 587 days) than patients with
>77% of baseline concentrations of HER2/neu ECD (median
217 days). A similar trend in the prediction of progression-free
survival was observed in the subcohort of patients treated with
a combination of trastuzumab and taxane.
One of the limitations of this study is that we evaluated a
selected population, since all patients have some degree of
HER2 expression in their primary tumors. However, approxi-
mately two-thirds of HER2/neu tissue-positive patients do not
respond to single-agent trastuzumab [15], and approximately
a third of HER2/neu tissue-positive patients do not respond to
trastuzumab in combination with chemotherapy [15,25].
Serum HER2/neu allows for real-time assessment of HER2
status, which could be quantified, and because it is a noninva-
sive procedure repeated testing is possible to determine the
change in HER2/neu concentrations. Therefore, we believe
that serum HER2 ECD concentrations in patients with meta-
static disease complements the data regarding tissue expres-
sion at the time of initial diagnosis (generally, HER2/neu status
is assessed in primary breast cancer specimens, not in meta-
static deposits).
Conclusion
This article does not advocate using baseline serum HER2/
neu to predict the efficacy of trastuzumab (Herceptin) therapy.
However, it does show value in using the delta change in
HER2/neu ECD from baseline to 2 to 4 weeks after the start
of therapy. Monitoring efficacy during the course of therapy
would allow clinicians to make necessary adjustments to drug
combination or even prompt them to follow up patients more
frequently. Our hypotheses are currently being tested in a pro-
spective, multicenter clinical trial.
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